STAMFORD, Conn., June 12, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the first quarter of fiscal 2026, which ended May 4, 2025. Shawn Nelson, Chief Executive Officer, stated, “Our first quarter performance was inline with our expectations to capitalize on secular initiatives to drive growth. Notably, we delivered ...

Core Insights - Bolt Biotherapeutics announced promising preclinical results for its next-generation Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs) targeting CEACAM5 and PD-L1 at the AACR Annual Meeting [1][2] - The CEA-targeted ISAC demonstrated complete and durable anti-tumor responses in mice and was well-tolerated in non-human primates (NHPs) [2][5] - PD-L1 ISACs showed the ability to activate and reprogram PD-L1-expressing myeloid cells, promoting both innate and adaptive anti-tumor immunity [5][6] Group 1: CEA-targeted ISAC - The CEA ISAC is designed with a fully human antibody that specifically targets CEACAM5, commonly found in gastrointestinal cancers [2][4] - It enhances phagocytosis of CEA-positive tumor cells and stimulates the production of immune-activating cytokines such as IL-12p70, IFNg, and TNFa [2][5] - In a non-GLP NHP toxicity study, the CEA ISAC was well-tolerated at doses up to 15 mg/kg, with no significant drug-related adverse events observed [5] Group 2: PD-L1 ISAC - The PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist, targeting both tumor and immune cells expressing PD-L1 [3][5] - It has shown complete regressions and the induction of immunological memory in models resistant to PD-1/PD-L1 checkpoint inhibitors [5] - The efficacy of PD-L1 ISACs does not rely on the blockade of the PD-1/PD-L1 axis, suggesting a complementary mechanism to existing therapies [5] Group 3: Company Overview - Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment [7] - The company's pipeline includes BDC-3042, an agonist antibody targeting dectin-2, and BDC-4182, a next-generation Boltbody™ ISAC targeting claudin 18.2, with clinical trials expected to begin in Q2 2025 [7]